Sevenfact (Coagulation Factor VIIa [Recombinant]-Jncw) for Haemophilia

Overview
Sevenfact is approved by the U.S. Food and Drug Administration (FDA) for the treatment and control of bleeding episodes in adults and adolescents (12 years and older) who have hemophilia A or B with inhibitors. It is not indicated for treating congenital factor VII (7) deficiency. Sevenfact is also known by its drug name, coagulation factor VIIa (recombinant)-jncw.

Sevenfact is a coagulation factor concentrate. It works by helping the blood to clot in people who have developed inhibitors (antibodies) against factor VIII (8) or IX (9), which are commonly used to treat hemophilia A and B.

How do I take it?
Prescribing information states that Sevenfact is given by intravenous (IV) infusion after reconstitution. For mild to moderate bleeding episodes, a dose may be repeated every three hours or a single higher dose may be used, followed by additional doses if needed. For severe bleeding, a higher initial dose is typically given, followed by smaller doses every two hours if necessary. Sevenfact should be administered exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Sevenfact include headache, dizziness, discomfort at the infusion site, infusion-site hematoma (bruising), infusion-related reaction, and fever.

Rare but serious side effects may include arterial or venous thrombotic events (blood clots in arteries or veins), activation of the coagulation system, and severe hypersensitivity reactions including anaphylaxis (a life-threatening allergic reaction).

For more information about this treatment, visit:
Label: Sevenfact — Coagulation Factor VIIa Recombinant Human Kit